Four corners reach a user fee deal
Top health lawmakers in the House and Senate reached an agreement to reauthorize the FDA’s user fee programs, but the path forward appears rocky.
Stay updated with breaking news from Jane Axelrad. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top health lawmakers in the House and Senate reached an agreement to reauthorize the FDA’s user fee programs, but the path forward appears rocky.
Share this article Share this article ALEXANDRIA, Va., April 30, 2021 /PRNewswire/ -- A 2020 FDA-funded report published by the National Academies of Sciences, Engineering, and Medicine (NASEM) on the safety and utility of compounded hormones is compromised by potential bias, conflicts of interest and bad science—so says an independent, third-party analysis of the NASEM report released today. The Food and Drug Administration (FDA) touted the NASEM report, which recommended restrictions on compounded hormone therapy, as "independent" and "comprehensive," but in fact it was neither. That's o...